TNR Grand Rounds - Update on Biosimilars

Save

This week's Tuesday Nite Rheumatology featured Dr Jonathan Kay (U Mass) who gave an update on Biosimilars and took questions the subject. The program was moderated by Dr. Jack Cush.

First Look at COVID-19 Global Rheumatology Alliance Registry

Save

Gianfresco et al have published the first peer-reviewed analysis of COVID-19 infected, rheumatic disease patients entered into the Rheumatology Global Alliance registry; showing that a) rheumatic disease patient can be infected with COVID-19, b) that DMARD and biologic use has no apparent effect on outcomes and c) steroid increase and TNF inhibitor decrease the odds of hospitalization.

RheumNow Podcast - Rheumatic Patients with COVID (5.29.20)

Save

Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com.

TNR Grand Rounds - Cytokine Storm Syndromes

Save

This week's Tuesday Nite Rheumatology featured Dr Randy Cron from the University of Alabama - Birmingham as he spoke and took questions on the immunology, immunopathogenesis and treatment of Cytokine Storm Syndrome, especially as they relate to COVID-19 and rheumatic disease patients. The program was moderated by Dr. Jack Cush.

Low Risk of COVID-19 Pneumonia in Rheumatic Patients

Save

A current letter in the Annals of Rheumatic Disease details the rheumatic disease patient cohort outcomes from the University of Siena, Italy showing only 2 cases of COVID-19 among 859 patients treated with tsDMARDs and bDMARDs.

No Certain Link between Biologics and Melanoma Risk

Save

A review of available data fails to show an increased risk of melanoma in IMID (inflammatory bowel disease, rheumatoid arthritis, and psoriasis) patients treated with systemic biologic therapies.  

Anti-TNF and CNS Events: The Link Strengthens

Save

Patients with autoimmune diseases who were treated with tumor necrosis factor (TNF) inhibitors had an increased risk of developing inflammatory central nervous system (CNS) adverse events, a nested case-control study found.

TNR - COVID-Rheumatology Registry & COVID in OZ

Save

This week's Tuesday Nite Rheumatology features presentations and interviews with Drs. Peter Nash and Philip Robinson. Dr. Robinson presents latest data on the Rheum-Covid.org Registry, that he helped establish under the Global Rheumatology Alliance. Dr. Nash presents the impact of COVID in Australia and pragmatic COVID management.

High Dose Anakinra Effective in COVID-19

Save

Anakinra was studied in 29 COVID(+) patients with respiratory distress and high inflammatory markers (CRP or ferritin) and compared to non-anakinra patients, those on anakinra had better survival (90% vs. 56% ;p=0·009) and greater improvements in CRP and pulmonary function (72% vs 50%) compared to controls at day 21.

Secukinumab Better than Adalimumab - Maybe?

Save

The EXCEED study was a head-to-head trial of secukinumab (SEC) versus adalimumab (ADA) as first-line monotherapy in psoriatic arthritis (PsA) patients; this 52 week trial showed that while SEC failed to achieve clinical superiority over ADA, SEC treated patients demonstrated higher

Biologic Dose Cuts Feasible in RA

Save

Many patients with rheumatoid arthritis (RA) who achieved remission or low disease activity on biologic treatment were able to reduce the dose of their biologic, particularly if they were also on methotrexate, a retrospective study found.

German Society of Rheumatology COVID Pandemic Recommendations

Save

The Annals of Rheumatic Disease has published the preliminary recommendations of the German Society of Rheumatology for the management of Inflammatory rheumatic diseases patients during the SARS-CoV-2/Covid-19 pandemic.

These preliminary recommendations are based on an expert consensus from 17 experienced German rheumatologists.

TNF Inhibitors Reduce and Stabilize Coronary Plaque

Save

Arthritis & Rheumatology reports that biologic (bDMARD) use in rheumatoid arthritis may decrease cardiovascular disease risk by retarding coronary plaque formation and progression (especially non‐calcified and low‐attenuation plaque).

RheumNow Podcast – In Times of Trouble (4.24.20)

Save

Dr Jack Cush reviews the news, journal reports, twitter feed and COVID developments from the past week on RheumNow.com

Certolizumab Pegol: A Safe And Efficient Treatment In Patients With Uveitis During Pregnancy: Conclusion: CZP seems to be effective and safe in female patients with uveitis during pregnancy and neonates. Abstract AB1055 #EULAR2020 @RheumNow https://t.co/MzeZKBawTg